Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI

Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI) have been elevated to Zacks Rank #1 (Strong Buy) status, driven by positive earnings estimate revisions and their respective value and growth profiles. Collegium, a specialty pharmaceutical company, is noted for its 'A' Value Score, trading at 5x forward earnings with projected 20% top-line and 9% bottom-line growth this year. Masimo, a non-invasive health monitoring provider, exhibits an 'A' Growth Score, with annual earnings anticipated to spike 20% in FY25 to $5.30 per share. Both stocks are presented as compelling investment opportunities for growth and value, concurrently offering a defensive hedge within the medical sector amidst broader market highs.

Analysis

Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI) have both received Zacks Rank #1 (Strong Buy) ratings, underpinned by positive revisions to their earnings per share (EPS) estimates. Collegium is presented as a compelling value opportunity within the specialty pharmaceutical space, trading at a significant discount with a 5x forward P/E ratio compared to its industry average of 15.5x. This valuation is coupled with strong fundamental projections, including 20% top-line and 9% bottom-line growth expected for the current year, and an EPS forecast exceeding $7 per share, distinguishing it from many unprofitable, speculative peers. Conversely, Masimo is highlighted as a growth-oriented investment in the medical instruments sector. Its 'A' Growth Score is justified by a projected 20% spike in annual earnings for FY25 to $5.30 per share, with a further 7% increase forecasted for FY26. This growth outlook supports its valuation premium, as it trades at 26.5x forward earnings versus the industry average of 23.5x. The article frames both stocks as attractive not only for their distinct value and growth profiles but also as a potential defensive hedge against market volatility, given the broader indexes are near all-time highs.

Key Decisions for Investors

• Value-oriented investors should evaluate Collegium Pharmaceutical, as it trades at a significant discount to its industry at 5x forward earnings despite projections for 20% top-line growth this year.
• For investors prioritizing growth, Masimo Corporation presents a clear opportunity with a 20% EPS growth forecast for FY25, though its slight valuation premium at 26.5x forward earnings warrants consideration.
• Given that broader markets are near all-time highs, investors could consider an allocation to these medical stocks as a defensive measure that combines both value and growth characteristics.
• Monitor upcoming earnings releases for both companies to validate that the positive earnings revisions materialize into actual performance, thereby substantiating their 'Strong Buy' ratings.